Navigation Links
Abbott's SIMCOR ® ( niacin extended-release / simvastatin ) Receives FDA Approval for New Dosage Strengths
Date:7/28/2010

ABBOTT PARK, Ill., July 28 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication.  The new SIMCOR dosage strengths combine 40 mg of simvastatin – the most commonly prescribed dose of simvastatin – with either 500 mg or 1,000 mg of niacin extended-release.  SIMCOR is the first treatment to combine Abbott's proprietary niacin extended-release and simvastatin, the most commonly used statin.  

SIMCOR is a prescription medication used along with diet in people who cannot control their cholesterol levels by diet and exercise alone.  SIMCOR is approved to raise HDL "good " cholesterol and lower levels of elevated total cholesterol, LDL " bad" cholesterol and triglycerides.  SIMCOR is a combination medicine used when treatment with simvastatin alone or niacin extended-release alone is not considered adequate.  No additional benefit of SIMCOR on heart disease over and above that shown for simvastatin alone and niacin alone has been demonstrated.  

"Approval of the new SIMCOR dosage strengths means that physicians and patients now have more options to treat complex lipid disease," said Eugene Sun, M.D., vice president, Global Pharmaceutical Development, Abbott.  

SIMCOR was approved by the FDA in February 2008 in the following strengths: 500/20 mg, 750/20 mg and 1,000/20 mg.  The original FDA approval was supported by results from the SEACOAST trial, which demonstrated efficacy and safety of SIMCOR up to doses of 2,000 mg niacin extended-release / 40 mg simvastatin daily in patients with mixed dyslipidemia and type II hyperlipidemia.  The SIMCOR 40 mg strengths will be available in early August 2010.

Treatment guidelines endorsed by the National Cholesterol Education Program, the American College of Cardiology and the American Heart Association have called for more aggressive management of lipids, including a lower LDL goal for some patients, as well as more aggressive management of HDL and triglycerides.

Important Safety Information About SIMCOR

SIMCOR should not be used by people with liver problems, stomach ulcers, or serious bleeding problems; in women who are pregnant, may become pregnant, or nursing.  Unexplained muscle pain, tenderness, or weakness may be a sign of a serious but rare muscle disorder, from which rare cases of death have occurred.  This risk of these muscle side effects is increased when SIMCOR is taken with certain types of medicines.  SIMCOR is associated with increases in liver enzymes as measured by blood tests.  Blood tests should be performed before and during treatment with SIMCOR to check for liver problems.  SIMCOR should be used with caution by patients who consume large amounts of alcohol.  SIMCOR may cause an increase in blood sugar levels which should be monitored closely in patients with diabetes.  

Flushing (warmth, redness, itching, and/or tingling of the skin) is a common side effect that may subside after several weeks of consistent use.  Other common side effects include headache, itching, nausea, back pain, and diarrhea.  

More information about SIMCOR, including full prescribing information, is available on the Web site http://www.rxabbott.com/pdf/simcor_pi.pdf, or by calling Abbott Medical Information at 1-800-633-9110.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com. Media:


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
2. Slo-Niacin(R) Offers More Than 20 Years of Heart Health Support
3. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
4. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
5. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
6. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
7. Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
8. New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
9. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
10. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
11. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... in unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as ... premier society for this important science. , The Teratology Society ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, ... strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable ... management of complex spine deformity cases, particularly in children. , GSO’s focus is ...
(Date:4/24/2017)... ... , ... The Santana Telehealth Project was honored with the 2017 ATA Humanitarian ... Association’s annual conference, on April 23 in Orlando, FL. , “I am proud that ... of the poor and underserved in other parts of the world,” said Jonathan Linkous, ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, ... inhabiting the rarified air of pop and film stardom.(1) Not to be left out ... the smile. Grins now run the gamut from being encrusted with jewels and precious ...
Breaking Medicine News(10 mins):